Paradigme (LYMRIT-37-01)

About this trial

The purpose of this trial is to investigate the efficacy and safety of a new drug called Betalutin®. One dose of Betalutin® is given to patients. Betalutin® is an antibody which targets a protein on lymphoma cancer cells together with radioactivity to kill the cancer cells. Two doses of Betalutin® are used in this clinical trial and all patients receive Betalutin®. Patients will be requested to return to clinic for up to 5 years to have their cancer assessed and to collect any side effects.

Patient Profile

Patients with Follicular Lymphoma that did not respond to treatment or recurred after chemotherapy or immunotherapy treatment.

Where’s this trial being run?

St James’s Hospital, University Hospital Galway, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information


Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: Paradigme (LYMRIT-37-01)
Number: 18-15
Full Title:

A phase I/II study of lutetium (177Lu)-lilotomab satetraxetan (Betalutin®) antibody-radionuclide-conjugate for treatment of relapsed non-Hodgkin lymphoma.

Principal Investigator: Prof Elisabeth Vandenberghe (St James's Hospital)
Type: Industry Sponsored

Nordic Nanovector

Recruitment Started: Global: December 2012
Ireland: February 2019
Global Recruitment Target: 130
Ireland Recruitment Target: 9